Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2010 1
2011 1
2012 1
2013 4
2015 2
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission.
Kovarova M, Council OD, Date AA, Long JM, Nochi T, Belshan M, Shibata A, Vincent H, Baker CE, Thayer WO, Kraus G, Lachaud-Durand S, Williams P, Destache CJ, Garcia JV. Kovarova M, et al. Among authors: kraus g. PLoS Pathog. 2015 Aug 13;11(8):e1005075. doi: 10.1371/journal.ppat.1005075. eCollection 2015 Aug. PLoS Pathog. 2015. PMID: 26271040 Free PMC article.
Ovalbumin-containing core-shell implants suitable to obtain a delayed IgG1 antibody response in support of a biphasic pulsatile release profile in mice.
Amssoms K, Born PA, Beugeling M, De Clerck B, Van Gulck E, Hinrichs WLJ, Frijlink HW, Grasmeijer N, Kraus G, Sutmuller R, Simmen K, Baert L. Amssoms K, et al. Among authors: kraus g. PLoS One. 2018 Aug 30;13(8):e0202961. doi: 10.1371/journal.pone.0202961. eCollection 2018. PLoS One. 2018. PMID: 30161264 Free PMC article.
Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study.
Beugeling M, Amssoms K, Cox F, De Clerck B, Van Gulck E, Verwoerd JA, Kraus G, Roymans D, Baert L, Frijlink HW, Hinrichs WLJ. Beugeling M, et al. Among authors: kraus g. Pharmaceutics. 2019 Oct 3;11(10):510. doi: 10.3390/pharmaceutics11100510. Pharmaceutics. 2019. PMID: 31623333 Free PMC article.
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Azijn H, Tirry I, Vingerhoets J, de Béthune MP, Kraus G, Boven K, Jochmans D, Van Craenenbroeck E, Picchio G, Rimsky LT. Azijn H, et al. Among authors: kraus g. Antimicrob Agents Chemother. 2010 Feb;54(2):718-27. doi: 10.1128/AAC.00986-09. Epub 2009 Nov 23. Antimicrob Agents Chemother. 2010. PMID: 19933797 Free PMC article.
Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1.
Nischang M, Sutmuller R, Gers-Huber G, Audigé A, Li D, Rochat MA, Baenziger S, Hofer U, Schlaepfer E, Regenass S, Amssoms K, Stoops B, Van Cauwenberge A, Boden D, Kraus G, Speck RF. Nischang M, et al. Among authors: kraus g. PLoS One. 2012;7(6):e38853. doi: 10.1371/journal.pone.0038853. Epub 2012 Jun 13. PLoS One. 2012. PMID: 22719966 Free PMC article.
Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.
Baert L, van 't Klooster G, Dries W, François M, Wouters A, Basstanie E, Iterbeke K, Stappers F, Stevens P, Schueller L, Van Remoortere P, Kraus G, Wigerinck P, Rosier J. Baert L, et al. Among authors: kraus g. Eur J Pharm Biopharm. 2009 Aug;72(3):502-8. doi: 10.1016/j.ejpb.2009.03.006. Epub 2009 Mar 27. Eur J Pharm Biopharm. 2009. PMID: 19328850
13 results